KR102758037B1 - Tg02의 다형성 형태 - Google Patents

Tg02의 다형성 형태 Download PDF

Info

Publication number
KR102758037B1
KR102758037B1 KR1020207007701A KR20207007701A KR102758037B1 KR 102758037 B1 KR102758037 B1 KR 102758037B1 KR 1020207007701 A KR1020207007701 A KR 1020207007701A KR 20207007701 A KR20207007701 A KR 20207007701A KR 102758037 B1 KR102758037 B1 KR 102758037B1
Authority
KR
South Korea
Prior art keywords
cancer
cell
tumor
carcinoma
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007701A
Other languages
English (en)
Korean (ko)
Other versions
KR20200078481A (ko
Inventor
로버트 케이. 맨스필드
트레이시 패롯
Original Assignee
코테라 바이오사이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코테라 바이오사이언스 인코포레이티드 filed Critical 코테라 바이오사이언스 인코포레이티드
Publication of KR20200078481A publication Critical patent/KR20200078481A/ko
Application granted granted Critical
Publication of KR102758037B1 publication Critical patent/KR102758037B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207007701A 2017-08-18 2018-08-17 Tg02의 다형성 형태 Active KR102758037B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547157P 2017-08-18 2017-08-18
US62/547,157 2017-08-18
PCT/US2018/000264 WO2019035985A1 (en) 2017-08-18 2018-08-17 POLYMORPHIC FORM OF TG02

Publications (2)

Publication Number Publication Date
KR20200078481A KR20200078481A (ko) 2020-07-01
KR102758037B1 true KR102758037B1 (ko) 2025-01-22

Family

ID=65359869

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007701A Active KR102758037B1 (ko) 2017-08-18 2018-08-17 Tg02의 다형성 형태

Country Status (14)

Country Link
US (4) US10544162B2 (enExample)
EP (2) EP3668876B1 (enExample)
JP (1) JP7250764B2 (enExample)
KR (1) KR102758037B1 (enExample)
CN (1) CN111372934B (enExample)
AU (1) AU2018317865B2 (enExample)
CA (1) CA3073270A1 (enExample)
ES (1) ES2977589T3 (enExample)
IL (1) IL272697B2 (enExample)
MX (1) MX2020001875A (enExample)
RU (1) RU2020111019A (enExample)
SG (1) SG11202001441WA (enExample)
TW (1) TWI785098B (enExample)
WO (1) WO2019035985A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230020549A (ko) 2016-03-24 2023-02-10 코테라 바이오사이언스 인코포레이티드 Tg02를 사용한 암의 치료
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型
WO2020219606A1 (en) 2019-04-22 2020-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of erk5 inhibitors for treating gliomas in pediatric subjects
CN110664760B (zh) * 2019-10-28 2020-10-23 浙江大学 一种负载vegfr靶向抑制剂的药物载体及其制备方法和应用
WO2024031406A1 (en) * 2022-08-10 2024-02-15 Xiang Li Idh mutations as biomarkers for zotiraciclib therapy
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用
CN115305251B (zh) * 2022-08-30 2023-06-27 中国农业科学院北京畜牧兽医研究所 Ap2-mybl2分子模块在调控原花色素生物合成中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120148661A1 (en) 2009-04-15 2012-06-14 Poniard Pharmaceuticals, Inc. High bioavailability oral picoplatin anti-cancer therapy
US20130150378A1 (en) * 2010-02-05 2013-06-13 Robert K. Mansfield Solid state forms of macrocyclic kinase inhibitors

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001011A1 (en) 1980-09-24 1982-04-01 Corp Cetus Diagnostic method and probe
DE3381518D1 (de) 1982-01-22 1990-06-07 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
EP1472265A4 (en) 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA INTERFERENCE MEDIA INHIBITION OF THE EXPRESSION OF THE POLYCOMB GROUP EZH2 PROTEIN GENE USING A SHORT INTERFERING NUCLEIC ACID (SINA)
EP1537878B1 (en) 2002-07-03 2010-09-22 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
TWI525096B (zh) 2005-11-16 2016-03-11 Cti生技製藥有限公司 氧連接之嘧啶衍生物
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Mcl-1 억제제
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
JP4965623B2 (ja) 2009-09-30 2012-07-04 インターナショナル・ビジネス・マシーンズ・コーポレーション 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
CA2795765C (en) 2010-04-06 2020-07-07 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
EP2760452A4 (en) 2011-09-30 2015-04-01 Glaxosmithkline Llc METHODS OF TREATING CANCER
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
EP3536314A1 (en) 2012-03-12 2019-09-11 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
KR102702287B1 (ko) 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
AU2013331368A1 (en) 2012-10-15 2015-04-30 Epizyme, Inc. Methods of treating cancer
HUE040434T2 (hu) 2013-02-21 2019-03-28 Pfizer Szelektív CDK4/6 inhibitor szilárd alakjai
MY210104A (en) 2013-03-15 2025-08-27 Glaxosmithkline Ip Dev Ltd Anti-lag-3 binding proteins
KR20210143932A (ko) 2013-09-11 2021-11-29 메디뮨 리미티드 종양 치료용 항-b7-h1 항체
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
KR20230020549A (ko) 2016-03-24 2023-02-10 코테라 바이오사이언스 인코포레이티드 Tg02를 사용한 암의 치료
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120148661A1 (en) 2009-04-15 2012-06-14 Poniard Pharmaceuticals, Inc. High bioavailability oral picoplatin anti-cancer therapy
US20130150378A1 (en) * 2010-02-05 2013-06-13 Robert K. Mansfield Solid state forms of macrocyclic kinase inhibitors

Also Published As

Publication number Publication date
EP3668876A4 (en) 2021-04-28
AU2018317865A1 (en) 2020-03-19
JP2020531463A (ja) 2020-11-05
SG11202001441WA (en) 2020-03-30
IL272697A (en) 2020-04-30
KR20200078481A (ko) 2020-07-01
ES2977589T3 (es) 2024-08-27
TW201920199A (zh) 2019-06-01
RU2020111019A (ru) 2021-09-20
US12043630B2 (en) 2024-07-23
MX2020001875A (es) 2020-07-29
EP3668876A1 (en) 2020-06-24
TWI785098B (zh) 2022-12-01
IL272697B1 (en) 2023-08-01
AU2018317865B2 (en) 2023-03-16
EP4364741A2 (en) 2024-05-08
CA3073270A1 (en) 2019-02-21
US20240254142A1 (en) 2024-08-01
US20240254141A1 (en) 2024-08-01
US20190055263A1 (en) 2019-02-21
EP4364741A3 (en) 2024-07-03
JP7250764B2 (ja) 2023-04-03
RU2020111019A3 (enExample) 2022-03-18
US20200262843A1 (en) 2020-08-20
CN111372934A (zh) 2020-07-03
IL272697B2 (en) 2023-12-01
WO2019035985A1 (en) 2019-02-21
CN111372934B (zh) 2024-04-26
EP3668876B1 (en) 2024-01-24
US10544162B2 (en) 2020-01-28

Similar Documents

Publication Publication Date Title
US20240156824A1 (en) Treatment of cancer with tg02
US20240254142A1 (en) Polymorphic form of tg02 for treating cancer
EP3430171B1 (en) Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
JP2022027788A (ja) 固形腫瘍を有する患者をクラス分けするための方法
CN101932724B (zh) 胃肠癌的增生标签及预后
Zhang et al. Identification of a Novel ECM Remodeling Macrophage Subset in AKI to CKD Transition by Integrative Spatial and Single‐Cell Analysis
US20220185886A1 (en) Methods for identifying biomarkers to predict treatment response
HK40106713A (en) Polymorphic form of tg02
JP2024541909A (ja) 乳がんの腫瘍微小環境タイプ
CA3018875C (en) Treatment of cancer with tg02
US20240139175A1 (en) Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
HK40025378A (en) Polymorphic form of tg02
HK40025378B (en) Polymorphic form of tg02
HK1261788A1 (en) Treatment of cancer with tg02
HK1261788B (en) Treatment of cancer with tg02
JP7554779B2 (ja) 処置レジメンを調節する方法
Kurimoto et al. MYC/BCL2 double-hit Lymphoma in a patient with rheumatoid arthritis associated with methotrexate treatment
Ferrena Molecular and Clinical Implications of SKP2 Inhibition in Osteosarcoma
KR20190079801A (ko) 방사선 치료에 대한 직장암의 예후 예측용 조성물
Fumet et al. Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T Cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite Stable Colorectal Cancer
KR101416502B1 (ko) 인간의 장암 진단용 키트
KR101416504B1 (ko) 인간의 장암 진단용 키트
KR20110039525A (ko) 인간의 장암 진단용 키트

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200316

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210817

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231026

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240416

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241017

PG1601 Publication of registration